Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals.
Atevirdine is a nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1). In this study we investigated the effect of atevirdine in asymptomatic antiretroviral naive HIV-infected patients with CD4+ cell counts of between 200 and 750 cells per mm3. Patients were randomized to receive 600 mg of atevirdine (n = 15) or a placebo (n = 15) three times a day for 12 weeks. There was no statistically significant effect of atevirdine on viral loads (HIV p24 antigen and HIV-1 RNA levels by PCR) or CD4+ cell counts. The data do not support the use of atevirdine as a monotherapy in the treatment of HIV-infected patients.
Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
A M
AM
Been-Tiktak
I
I
Williams
H M
HM
Vrehen
J
J
Richens
D
D
Aldam
A M
AM
van Loon
C
C
Loveday
C A
CA
Boucher
P
P
Ward
I V
IV
Weller
J C
JC
Borleffs
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D010879:Piperazines; C076632:atevirdine